TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32048808

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT) for childhood obesity, duration: 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT) for childhood obesity, sessions 10 to 20
Number of subjects: 0
Study: 32048889

Group type: EXPERIMENTAL
Intervention: Combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose
Number of subjects: 0
Study: 32049318

Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: peg-IFN treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of IL-12
Number of subjects: 0
Study: 32049638

Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2 h PG)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: iIFG
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: iIGT
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Normal FPG with elevated TGs, hypertension, moderate-to-severe non-alcoholic fatty liver disease or MetS
Number of subjects: 542
Study: 32049677

Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Number of subjects: 0
Study: 32049753

Group type: EXPERIMENTAL
Intervention: Turkish version of the Survey of Activities and Fear of Falling in the Elderly (SAFE-T)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SAFE-T activity level
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SAFE-T activity restriction
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SAFE-T fear of falling subscale
Number of subjects: 111
Study: 32049773

Group type: COMPARATOR
Intervention: Cohort A (no lopinavir/ritonavir resistance, stayed on second-line regimen)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Cohorts B, C, and D (increasing resistance, accessed novel ART regimens)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 545
Study: 32050231

Group type: EXPERIMENTAL
Intervention: Presbyopic posterior chamber pIOL (IPCL) implantation
Number of subjects: 17
Study: 32050447

Group type: EXPERIMENTAL
Intervention: Aerosolised plus intravenous vancomycin; dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; treatment not specified
Number of subjects: 0
Study: 32050956

Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 24
Study: 32051148

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized cardiovascular reflex tests
Number of subjects: 0
Study: 32051219

Group type: EXPERIMENTAL
Intervention: Mail-back envelope for opioid return
Number of subjects: 331
Study: 32051222

Group type: EXPERIMENTAL
Intervention: Iterative quality improvement interventions (altered physician workflow, standardized discharge checklists, physician workshops)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32052016

Group type: EXPERIMENTAL
Intervention: Mixed Meal Test (MMT) in AAs
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Hepatic IDE activity in AAs
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hepatic IDE and CEACAM-1 levels
Number of subjects: 83
Study: 32052264

Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg BID
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 mg BID
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg BID
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg BID
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 32052315

Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (HPR)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HPR and β-amyloid > 51 mg/dl
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HPR and MOTS-c < 167 ng/ml
Number of subjects: 121
Study: 32052473

Group type: EXPERIMENTAL
Intervention: Urelumab alone (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Urelumab plus rituximab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W plus rituximab 375 mg/m2)
Number of subjects: 106
Study: 32052523

Group type: EXPERIMENTAL
Intervention: Prednisolone-treated RTR
Number of subjects: 693
Study: 32052566

Group type: EXPERIMENTAL
Intervention: Increased positive symptoms
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Increased negative symptoms
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Increased positive symptoms at baseline
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Symptoms of depression at baseline
Number of subjects: 404
Study: 32053113

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive evaluations using the Consortium to Establish a Registry for Alzheimer's Disease Plus test battery.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measurement Information System Profile 29 and Hospital Anxiety and Depression Scale for assessing physical, mental, and social health.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale for screening postoperative delirium (POD).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, criteria for validation of POD.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Markers of (neuro)inflammation including interleukins, C-reactive protein, tumor necrosis factor alpha.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reevaluation of cognitive abilities 3 months postoperatively to investigate presence of POCD.
Number of subjects: 200
Study: 32053116

Group type: EXPERIMENTAL
Intervention: Geriatric hotline consultation
Number of subjects: 0
Study: 32053203

Group type: EXPERIMENTAL
Intervention: Analytical Treatment Interruption (ATI)
Number of subjects: 11
Study: 32053612

Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg once daily for 12 months
Number of subjects: 10
Study: 32053771

Group type: EXPERIMENTAL
Intervention: Celyvir (autologous MSCs carrying oncolytic adenovirus), administered intravenously, 2 × 10^9 cells weekly for 6 weeks
Number of subjects: 0
Study: 32054150

Group type: EXPERIMENTAL
Intervention: Immune checkpoint blocker (ICB) therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Palliative radiotherapy (RT)
Number of subjects: 127
Study: 32054467

Group type: EXPERIMENTAL
Intervention: High serum levels of soluble programmed death-ligand 1 (sPD-L1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low serum levels of soluble programmed death-ligand 1 (sPD-L1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Serum levels of IL-7
Number of subjects: 68
Study: 32054623

Group type: EXPERIMENTAL
Intervention: Community Health Representatives (CHRs) involvement in the clinical team
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: COPE coaching materials
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Face-to-face COPE trainings with CHRs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Access to electronic health records for CHRs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Requests for designated personnel for referrals
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Formal system to record CHR training modules
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Integration of community health workers into clinic-based teams
Number of subjects: 13
Study: 32054625

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) collected during a 1-year follow-up period.
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Data collected from patient medical records and national compulsory registries.
Number of subjects: 3000
Study: 32055239

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms applied to 40 proteins
Number of subjects: 24
Study: 32055404

Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study: 32055787

Group type: EXPERIMENTAL
Intervention: Varenicline preloading for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard varenicline preloading for 1 week
Number of subjects: 0
Study: 32055790

Group type: EXPERIMENTAL
Intervention: Intervention (specific appointments for further examinations by quality-assured doctors at a designated local hospital)
Number of subjects: 9936

Group type: COMPARATOR
Intervention: Control (free school-based eye screening, usual practice)
Number of subjects: 9936
Study: 32055862

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Corticosteroids pretreatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Apheresis pretreatment
Number of subjects: 204
Study: 32055965

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study: 32056017

Group type: EXPERIMENTAL
Intervention: STE-derived parameters
Number of subjects: 48
Study: 32056537

Group type: EXPERIMENTAL
Intervention: SKIP intervention
Number of subjects: 33
Study: 32056676

Group type: EXPERIMENTAL
Intervention: Pedometer plus a website with feedback, goal-setting, disease education, and a community forum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pedometer alone (control)
Number of subjects: 0
Study: 32056939

Group type: EXPERIMENTAL
Intervention: Anxious individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety and older age
Number of subjects: 0
Study: 32057467

Group type: EXPERIMENTAL
Intervention: Nivolumab 240mg Q2W for 6 infusions and ipilimumab 1mg/kg Q6W for 2 infusions in neoadjuvant setting, followed by nivolumab 480mg Q4W for 9 infusions post-surgery.
Number of subjects: 32
Study: 32057706

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Computed tomography coronary angiography (CTA)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 206
Study: 32058557

Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy (fluorouracil 2400 mg/m2 over 46 hours; oxaliplatin 85 mg/m2; irinotecan 180 mg/m2 for UGT1A1 genotype 6/6, 135 mg/m2 for 6/7, or 90 mg/m2 for 7/7; prophylactic peg-filgastrim 6 mg) for 4 cycles before and after surgery.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy with trastuzumab for ERBB2-positive tumors.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy (including trastuzumab for ERBB2-positive tumors)
Number of subjects: 36
Study: 32058843

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at recommended doses for expansion (5.4 or 6.4 mg/kg) administered intravenously once every 3 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg
Number of subjects: 54
Study: 32058873

Group type: EXPERIMENTAL
Intervention: Adherence to study-guideline (SG) for post-operative RT
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Less RT than predefined target volumes
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: More extensive RT than according to SG
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Intermediate-risk group adherence to SG
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Substantial deviation from SG for post-operative RT
Number of subjects: 848
Study: 32059085

Group type: EXPERIMENTAL
Intervention: Bortezomib added to arsenic trioxide (ATO)
Number of subjects: 22
Study: 32059193

Group type: EXPERIMENTAL
Intervention: Modified spine MRI protocol (3D sequences modified to 2D, reduced number of slices)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Routine clinical spine MRI protocols
Number of subjects: 9
Study: 32059615

Group type: EXPERIMENTAL
Intervention: OneTouch Verio Reflect blood glucose monitor
Number of subjects: 0
Study: 32059714

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 48
Study: 32059719

Group type: EXPERIMENTAL
Intervention: Medical treatment (382 patients)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Surgical treatment (589 patients, 388 RYGB and 201 SG)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Control group (156 patients left the study without treatment)
Number of subjects: 971
Study: 32059815

Group type: EXPERIMENTAL
Intervention: Fish oil intravenous lipid emulsion (FOLE) 1 g/kg/day
Number of subjects: 123

Group type: COMPARATOR
Intervention: Soybean oil intravenous lipid emulsion (SOLE) up to 3 g/kg/day
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: FOLE
Number of subjects: 123

Group type: COMPARATOR
Intervention: SOLE
Number of subjects: 123
Study: 32060053

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously on day 1 and capecitabine 1000 mg/m²
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 30
Study: 32060062

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32060165

Group type: EXPERIMENTAL
Intervention: Intravenous or intramuscular thiamine (100 mg daily for a minimum of 3 days)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Baseline assessments including physical examination, echocardiogram, and venous blood draw for thiamine biomarkers
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Follow-up assessments including physical examinations and echocardiograms at specified intervals
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Logistic regression models to identify predictors of TRD
Number of subjects: 662

Group type: COMPARATOR
Intervention: Comparison with a frequency-matched community-based cohort of mother-child pairs (n=265)
Number of subjects: 662
Study: 32060403

Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 67
Study: 32060608

Group type: EXPERIMENTAL
Intervention: Flagellin co-exposure with ovalbumin in a murine model of allergic asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of flagellin in house dust of asthma patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dominant-negative polymorphism in TLR5 (rs5744168)
Number of subjects: 0
Study: 32060867

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 198
Study: 32061408

Group type: EXPERIMENTAL
Intervention: High-increasing group (n=337)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Moderate-increasing group (n=1178)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Low-increasing group (n=1324)
Number of subjects: 2839
Study: 32061453

Group type: EXPERIMENTAL
Intervention: Single ketamine infusion (0.5 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (0.5 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Baseline CBF in the fusiform
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acute changes in CBF in visual areas
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison with control group (N = 18, mean age = 36.11 ± 14.5 SD, 57% female)
Number of subjects: 22
Study: 32061464

Group type: COMPARATOR
Intervention: 068 intervention arm
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Higher-risk group
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Lower-risk group
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Ever having had sex
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Borrowing money
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Supporting more gender-equitable norms
Number of subjects: 907
Study: 32061579

Group type: EXPERIMENTAL
Intervention: Severity of superficial dyspareunia
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Previous difficulty conceiving
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Currently trying to conceive
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Severity of deep dyspareunia
Number of subjects: 300
Study: 32062041

Group type: EXPERIMENTAL
Intervention: Vedolizumab therapy
Number of subjects: 620
Study: 32062172

Group type: EXPERIMENTAL
Intervention: Combined FFR and CFR measurements
Number of subjects: 455

Group type: COMPARATOR
Intervention: Medical treatment for lesions with FFR (≤0.8) and CFR (<2.0)
Number of subjects: 455
Study: 32062661

Group type: EXPERIMENTAL
Intervention: Presence of Patent Foramen Ovale (PFO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No PFO
Number of subjects: 112
Study: 32062681

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot (LAN) combined with peptide receptor radionuclide therapy (PRRT)
Number of subjects: 40
Study: 32063120

Group type: EXPERIMENTAL
Intervention: Deferred revascularization with FFR >0.75
Number of subjects: 879
Study: 32063340

Group type: EXPERIMENTAL
Intervention: Multivariable model including European System for Cardiac Operative Risk Evaluation II and preoperative haemoglobin
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Multivariable model including European System for Cardiac Operative Risk Evaluation II, preoperative haemoglobin, and pre-specified frailty characteristics (polypharmacy, gait speed, physical disability, preoperative health-related quality of life, and living alone)
Number of subjects: 537
Study: 32063371

Group type: EXPERIMENTAL
Intervention: Kidscreen questionnaire
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wechsler Children's Intelligence Scale, NEuroPSYchological assessment, Rey figure test
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Krickenbeck score
Number of subjects: 15
Study: 32063492

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/d) with ADT and RT (66 Gy)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Salvage RT and ADT
Number of subjects: 38
Study: 32063605

Group type: EXPERIMENTAL
Intervention: TG01/GM-CSF with adjuvant gemcitabine (high antigen burden)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TG01/GM-CSF with adjuvant gemcitabine (modified vaccination schedule with reduced antigen burden)
Number of subjects: 32
Study: 32063845

Group type: EXPERIMENTAL
Intervention: Mephedrone plus alcohol (200 mg mephedrone + 0.8 g/kg alcohol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mephedrone alone (200 mg mephedrone + placebo alcohol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alcohol alone (placebo mephedrone + 0.8 g/kg ethanol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (placebo mephedrone + placebo alcohol)
Number of subjects: 11
Study: 32064291

Group type: EXPERIMENTAL
Intervention: Neuromuscular shoulder exercise (SINEX)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care exercise (HOMEX)
Number of subjects: 56
Study: 32064663

Group type: EXPERIMENTAL
Intervention: Digital treatment augmentation study
Number of subjects: 187
Study: 32064766

Group type: EXPERIMENTAL
Intervention: Bottom-up costing method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Top-down costing method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ART drug costs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cost variability
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Missing capacity costs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 10
Study: 32065043

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) during exercise as measured by sports watch data
Number of subjects: 177
Study: 32065330

Group type: EXPERIMENTAL
Intervention: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD) for 8 weeks (Cohort 1) or 12 weeks (Cohort 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD)
Number of subjects: 33
Study: 32065359

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg/ezetimibe 10 mg once daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 136
Study: 32065586

Group type: EXPERIMENTAL
Intervention: ARC-HBR criteria
Number of subjects: 12121
Study: 32065631

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Not applicable (historical controls)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Not applicable (intracellular measurements)
Number of subjects: 15
Study: 32066275

Group type: EXPERIMENTAL
Intervention: Automated adaptive atlas algorithm for segmenting the left ventricle on CAC-CT, extracting 107 radiomics features.
Number of subjects: 1982

Group type: EXPERIMENTAL
Intervention: Logistic regression models using different feature selection methods based on CAC-CT radiomics, sex, height, and body surface area.
Number of subjects: 1982
Study: 32066475

Group type: EXPERIMENTAL
Intervention: Semi-structured single interviews with former PMD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interprofessional focus groups with health and social care professionals
Number of subjects: 24
Study: 32066540

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily, taken orally, until progression or unacceptable toxicity.
Number of subjects: 34
Study: 32066561

Group type: EXPERIMENTAL
Intervention: Reading Centres (RCs)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Clinicians
Number of subjects: 205
Study: 32066588

Group type: EXPERIMENTAL
Intervention: Group A (vCT and rCT)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Group B (vCT and rectally untested)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Group C (single vCT)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Group D (single rCT)
Number of subjects: 555
Study: 32066601

Group type: EXPERIMENTAL
Intervention: Functional decline during hospitalization
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Functional decline group
Number of subjects: 3555

Group type: COMPARATOR
Intervention: No functional decline group
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Independent risk factors for functional decline
Number of subjects: 3555
Study: 32066622

Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent placement
Number of subjects: 0
Study: 32066978

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 0